We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Tecentriq

News List

EU green light for Roche’s Tecentriq pharmatimes
September 26, 2017
Roche has received European Commission approval for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab) to treat specific lung and bladder cancers.
Europe recommends Tecentriq in bladder cancer, but efficacy doubts persist pharmaphorum
July 25, 2017
The European Union’s CHMP committee recommended 11 medicines on Friday, including five orphan drugs.
Roche's Tecentriq fails to increase survival in advanced bladder cancer study firstwordpharma
May 11, 2017
Roche announced Wednesday that the Phase III IMvigor211 study of Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial cancer (mUC) whose disease progressed during or after treatment...
MHRA accepts Roche's Tecentriq into Early Access to Medicines scheme pharmafile
January 26, 2017
The decision means that patients suffering from the illness could have access to the drug while it awaits decision from the UK and Europe’s regulatory bodies.

Previous page 1 2 3 4 5 6 7 Next page